Conference abstract · 22 Oct 2018
EditorialPublished 22 Dec 2011
Finally, A Routine Use for ES and iPS Cells
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
For more than a decade now the scientific community has been waiting for embryonic stem (ES) and induced pluripotent stem (iPS) cells to mature from an interesting research observation to a useful clinical tool. Unfortunately, it has become readily apparent that there are many barriers to clinical implementation for both ES and iPS cells. Allogenicity and the threat of immune rejection by the host, the risk of teratogenicity and development of tumors in anatomical locations that would be life-threatening (e.g., the brain), and the time and cost involved to derive differentiated tissues for clinical use (estimated to be 6 months or more and in excess of $50,000 per tissue) have thwarted the rapid transition of these cells from the bench to the bedside. Although the use of iPS cells can alleviate the concern of immune rejection found with ES cells, it does not remove the other problems and reports of extensive genomic instability only serve to further limit this technology from clinical use. These issues have put this field under intense scrutiny which has increased costs as well as federal regulatory oversight. In fact, these difficulties have resulted in one of the major players in this field, Geron, to withdraw from these endeavors. It is doubtful that either ES or iPS cells would ever be given directly to patients, and it is very difficult to conceive of even bringing tissues and cells derived from either source to fruition for patient benefit (although some companies are trying).
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Factors related to the natural killer cell activity in subjects undergoing routine health screening
Case report · 25 Jun 2020
Initial Diagnosis of Psoriasis and Final Diagnosis of Cutaneous T-Cell Lymphoma/SÃ?©zary Syndrome
Case report · 2020
Initial Diagnosis of Psoriasis and Final Diagnosis of Cutaneous T-Cell Lymphoma/Sézary Syndrome
Case report · 2014
Hurthle Cell Lesions- A Retrospective Review of Final Surgical Pathology
More from this journal
The newest in Journal of Bioengineering and Bioelectronics.
Review article · 2 Jun 2016
Nanomaterial-modified Flexible Micro-electrode Array by Electrophoretic Deposition of Carbon Nanotubes
Opinion · 16 May 2016
Self-pumping and Recovery Device Design for Molecule Trapping and Accelerator Use
Research article · 23 Jan 2016
Flow Fields during Formation of W/O and O/W Emulsions using μPIV
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioengineering and Bioelectronics
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “David T. Harris”
